Page last updated: 2024-09-04
abiraterone and niraparib
abiraterone has been researched along with niraparib in 1 studies
Compound Research Comparison
Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (niraparib) | Trials (niraparib) | Recent Studies (post-2010) (niraparib) |
---|---|---|---|---|---|
942 | 97 | 854 | 212 | 46 | 209 |
Protein Interaction Comparison
Protein | Taxonomy | abiraterone (IC50) | niraparib (IC50) |
---|---|---|---|
Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | 1.7564 | |
Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 0.0278 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0021 | |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.0021 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0021 | |
Protein mono-ADP-ribosyltransferase PARP14 | Homo sapiens (human) | 1.7378 | |
Protein mono-ADP-ribosyltransferase PARP10 | Homo sapiens (human) | 2.6153 | |
Protein mono-ADP-ribosyltransferase PARP12 | Homo sapiens (human) | 0.4367 | |
Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | 5.1293 | |
Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | 0.2306 | |
Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | 0.4076 | |
Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | 0.3797 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Bradic, B; Chi, KN; De Meulder, M; Espina, BM; Francis, P; Graff, JN; Hayreh, V; Hazra, A; Lattouf, JB; Mamidi, RNVS; Posadas, EM; Rezazadeh Kalebasty, A; Saad, F; Shore, ND; Yu, A; Zhu, E | 1 |
Trials
1 trial(s) available for abiraterone and niraparib
Article | Year |
---|---|
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Middle Aged; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Thiohydantoins | 2021 |